Hypertrophic cardiomyopathy in burnout phase
DOI:
https://doi.org/10.21615/cesmedicina.6244Keywords:
cardiomyopathy, hypertrophic, burnout stage, case study, magnetic resonance imaging, atrial fibrillationAbstract
Hypertrophic cardiomyopathy is a genetic entity characterized by left ventricular hypertrophy in the absence of other diseases as etiology. Patients are usually asymptomatic; however, the spectrum of presentation is wide and may include heart failure, outflow tract obstruction, arrhythmias, sudden death and the final stage also known as ''burnout phase''. The initial morphological assessment is performed with transthoracic echocardiography; however, cardiac magnetic resonance imaging is the gold standard to confirm the diagnosis. We present the case of a 43-year-old woman with a history of previously operated hypertrophic cardiomyopathy who was admitted to the emergency department decompensated, documenting progression to the "burnout" phase and her management. Although this phenotype is not common, it has prognostic and quality of life implications. Therefore, timely diagnosis and treatment can have an impact on these variables.
Downloads
References
Antunes M de O, Scudeler TL. Hypertrophic cardiomyopathy. IJC Hear Vasc. 2020;27:100503.
Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: An overview of genetics and management. Biomolecules. 2019;9(12):1–11.
Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 2018;379(7):655–68.
Brinkley DM, Wells QS, Stevenson LW. Avoiding Burnout from hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75(24):3044-3047. doi: 10.1016/j.jacc.2020.05.009. PMID: 32553257.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020;533–57.
Maron MS, Rowin EJ, Maron BJ. How to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(7):1–15.
Abad P, Asociacion Colombiana de Radiologia. Miocardiopatías. Dr. Pedro Abad Díaz - Conferencia Virtual [Internet]. Colombia: Asociacion Colombiana de Radiologia; 2018. Available from: http://www.acronline.org/ACR-Admin/NOTI-CCR/ArtMID/1061/ArticleID/5966/Miocardiopat237as-Dr-Pedro-Abad-D237az-Conferencia-Virtual
Heitner SB, Jacoby D, Lester SJ, Owens A, Wang A, Zhang D, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy a clinical trial. Ann Intern Med. 2019;170(11):741–8.
Zhang YP, He B. Mavacamten: a promising new target drug for the treatment of hypertrophic cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi [Internet]. 2021 Apr 24;49(4):310–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33874678
Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2020;396(10253):759–69. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067362031792X
Tower-Rader A, Ramchand J, Nissen SE, Desai MY. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Expert Opin Investig Drugs [Internet]. 2020;29(11):1171–8. Available from: https://www.tandfonline.com/doi/full/10.1080/13543784.2020.1821361
Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol [Internet]. 2020;75(21):2649–60. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109720348567
Cooper RM, Raphael CE, Liebregts M, Anavekar NS, Veselka J. New developments in hypertrophic cardiomyopathy. Can J Cardiol [Internet]. 2017;33(10):1254–65. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0828282X17303719
Nishimura RA, Seggewiss H, Schaff H V. Hypertrophic obstructive cardiomyopathy: Surgical myectomy and septal ablation. Circ Res. 2017;121(7):771–83.
Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, et al. Surgical Approaches to hypertrophic obstructive cardiomyopathy. Semin Thorac Cardiovasc Surg. 2018;30(2):125–8.
O’Neill L, Duytschaever M, Knecht S. Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: do not throw in the towel too fast! Europace [Internet]. 2021; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33930128
Ali A. Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management. J Atr Fibrillation [Internet]. 2018;10(5). Available from: http://www.jafib.com/published.php?type=full&id=1556
Santangeli P, Di Biase L, Themistoclakis S, Raviele A, Schweikert RA, Lakkireddy D, et al. Catheter Ablation of atrial fibrillation in hypertrophic cardiomyopathy. circ arrhythmia electrophysiology [Internet]. 2013;6(6):1089–94. Available from: https://www.ahajournals.org/doi/10.1161/CIRCEP.113.000339
Cui H, Schaff H V., Dearani JA, Lahr BD, Viehman JK, Geske JB, et al. Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy? J Thorac Cardiovasc Surg [Internet]. 2021;161(3):997-1006.e3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022522320324545
Bogachev-Prokophiev A V., Afanasyev A V., Zheleznev SI, Pivkin AN, Fomenko MS, Sharifulin RM, et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg [Internet]. 2018;155(4):1536-1542.e2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022522317318251
Caldeira D, Lopes LR, Cruz I, Almeida AR, Morgado G, Gomes C, Stuart B, Almeida S, Brandão L, Pereira H. The burnout stage of an apical hypertrophic cardiomyopathy. Int J Cardiol. 2014;177(3):e179-80. doi: 10.1016/j.ijcard.2014.08.092. Epub 2014 Aug 23. PMID: 25179554.
Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, et al. Impact of Advanced therapies for improving survival to heart transplant in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(8):986–96.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 CES Medicina
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Derechos de reproducción (copyright)
Cada manuscrito se acompañará de una declaración en la que se especifique que los materiales son inéditos, que no han sido publicados anteriormente en formato impreso o electrónico y que no se presentarán a ningún otro medio antes de conocer la decisión de la revista. En todo caso, cualquier publicación anterior, sea en forma impresa o electrónica, deberá darse a conocer a la redacción por escrito.
Plagios, duplicaciones totales o parciales, traduccones del original a otro idioma son de responsabilidad exclusiva de los autores el envío.
Los autores adjuntarán una declaración firmada indicando que, si el manuscrito se acepta para su publicación, los derechos de reproducción son propiedad exclusiva de la Revista CES Medicina.
Se solicita a los autores que proporcionen la información completa acerca de cualquier beca o subvención recibida de una entidad comercial u otro grupo con intereses privados, u otro organismo, para costear parcial o totalmente el trabajo en que se basa el artículo.
Los autores tienen la responsabilidad de obtener los permisos necesarios para reproducir cualquier material protegido por derechos de reproducción. El manuscrito se acompañará de la carta original que otorgue ese permiso y en ella debe especificarse con exactitud el número del cuadro o figura o el texto exacto que se citará y cómo se usará, así como la referencia bibliográfica completa.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
